Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,196 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06655259 | Combination of TURP and Standard Systemic Therapy for MPCa(CTUSMEP01) | recruiting | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05571618 | The Rechallenge of ADCs in MBC Patients | active not recruiting | — | 100 | Fudan UniversityOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06642948 |
| AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial(AiRE-MS) |
| recruiting |
| N/A |
| 80 |
| Fudan UniversityOTHER |
| 1 |
| Oct 15, 2024 |
| clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06635096 | The Safety and Efficacy of Multimodal Thermal Therapy in the Treatment of Early-stage Invasive Breast Cancer | not yet recruiting | N/A | 60 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06344767 | Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor | completed | — | 19 | Fudan UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT05594095 | SNF Platform Study of HR+/ HER2-advanced Breast Cancer | recruiting | Phase 2 | 620 | Fudan UniversityOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05628038 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer(TORCH-R) | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04508803 | Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer(CHANGEABLE) | completed | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas | withdrawn | N/A | 0 | Fudan UniversityOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06355440 | Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China | completed | N/A | 26 | Fudan UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05963490 | Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer(SLOT) | recruiting | Phase 2 | 108 | Fudan UniversityOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06166147 | A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection | recruiting | — | 276 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06551051 | ADC-induced Neurotoxicity Treated With Duloxetine | recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588179 | SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt | not yet recruiting | Phase 1 / Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588569 | Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors | active not recruiting | N/A | 20 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06591039 | A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China | recruiting | — | 20,000 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593548 | Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer | not yet recruiting | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06341556 | A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma | recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT05794698 | Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014) | completed | — | 827 | Fudan UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06331169 | Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer | recruiting | Phase 1 | 42 | Fudan UniversityOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06578286 | ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | not yet recruiting | Phase 2 | 44 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06578299 | Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer | not yet recruiting | Phase 4 | 100 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06501391 | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis | recruiting | Phase 2 | 54 | Fudan UniversityOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06393140 | The Study on the Mechanism of Radiotherapy-elicited Immune Response | unknown | — | 200 | Fudan UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06561620 | Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients | recruiting | Phase 4 | 592 | Fudan UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04764214 | SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs | completed | Phase 2 | 61 | Fudan UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06561022 | Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping(abemaSNF1/3) | unknown | Phase 2 | 260 | Fudan UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06545994 | A Prospective Cohort Study on the Serum Kisspeptin Levels Throughout Pregnancy in PCOS | unknown | — | 180 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06552858 | Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06553781 | A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma | not yet recruiting | N/A | 28 | Fudan UniversityOTHER | 0 | Aug 14, 2024 | clinicaltrials |
| NCT06553846 | A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06548178 | T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer | not yet recruiting | Phase 2 | 242 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06548763 | Oral Topotecan With Toripalimab for Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06475326 | Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 87 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06544460 | Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients | not yet recruiting | Phase 2 | 94 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06541288 | A Prospective Cohort Study Comparing AI Prediction Model With Imaging Assessment to Diagnose Lymph Node Metastasis in Cervical Cancer | not yet recruiting | N/A | 230 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06542354 | Prehabilitation During Neoadjuvant Chemoradiotherapy for Rectal Cancer | completed | N/A | 108 | Fudan UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06387628 | LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer | recruiting | Phase 2 | 74 | Fudan UniversityOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06530316 | RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer | recruiting | — | 48 | Fudan UniversityOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06503380 | Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer | recruiting | — | 1,000 | Fudan UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06525428 | Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer | recruiting | Phase 2 | 96 | Fudan UniversityOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06521788 | Artificial Intelligence Assisted Breast Ultrasound in Breast Cancer Screening(AIBU) | completed | N/A | 21,790 | Fudan UniversityOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06517004 | An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06513221 | A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab | not yet recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT04303988 | A Phase II Study of Triple-negative Breast Cancer Brain Metastases. | unknown | Phase 2 | 35 | Fudan UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06495827 | Predicting Response to Chemotherapy in Colorectal Cancer Via Multi-dimensional Analyses of the Tumor Associated Neutrophils | completed | — | 653 | Fudan UniversityOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT06313567 | Metronomic Capecitabine in Stage III Gastric Cancer | recruiting | Phase 3 | 722 | Fudan UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06355037 | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05229003 | Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials